Evidence map›Paper›PMID 37608247›Full record

ArticleBMC infectious diseases2023

Clinical burden of invasive Escherichia coli disease among older adult patients treated in hospitals in the United States.

Luis Hernandez-Pastor, Jeroen Geurtsen, Bryan Baugh, Antoine C El Khoury, Nnanya Kalu, Marjolaine Gauthier-Loiselle, Rebecca Bungay, Martin Cloutier, Michal Sarnecki, Elie Saade

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Adaptive Response ofAntibiotics (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 5 countries.

Luis Hernandez-PastorGlobal Market Access, Vaccines Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse, B-2340, Belgium. lhern107@its.jnj.com.
Jeroen GeurtsenMolecular Bacteriology & Bacterial Epidemiology, Janssen Vaccines & Prevention BV, Archimedesweg 4, Leiden, 2333 CN, The Netherlands.
Bryan BaughGlobal Medical Affairs, Janssen Research & Development, LLC, 1000 U.S. Route 202 South, Raritan, NJ, 08869, USA.
Antoine C El KhouryGlobal Market Access, Janssen Global Services, LLC, 1000 U.S. Route 202 South, Vaccines, Raritan, NJ, 08869, USA.
Nnanya KaluUS Vaccines Medical Affairs, Janssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, 08560, Titusville, NJ, USA.
Marjolaine Gauthier-LoiselleHealth Economics and Outcomes Research, Analysis Group, Inc, 1190 avenue des Canadiens- de-Montréal, Tour Deloitte, Suite 1500, H3B 0G7, Montreal, QC, Canada.
Rebecca BungayHealth Economics and Outcomes Research, Analysis Group, Inc, 1190 avenue des Canadiens- de-Montréal, Tour Deloitte, Suite 1500, H3B 0G7, Montreal, QC, Canada.
Martin CloutierHealth Economics and Outcomes Research, Analysis Group, Inc, 1190 avenue des Canadiens- de-Montréal, Tour Deloitte, Suite 1500, H3B 0G7, Montreal, QC, Canada.
Michal SarneckiClinical Development, Janssen Vaccines, Rehhagstrasse 79, 3018, Bern, Switzerland.
Elie SaadeDepartment of Medicine, Case Western Reserve University, Health Education Campus, 9501 Euclid Ave, 44106, Cleveland, OH, USA.
Group for Research in Decision Analysis · CAJanssen (United States) · USCase Western Reserve University · USJanssen (Belgium) · BEJanssen (Netherlands) · NLJanssen Scientific Affairs (United States)Janssen (Switzerland) · CH

Funding

Janssen Global Services, LLC Not Applicable
6 · The paper itself

Abstract

backgroundInvasive extraintestinal pathogenic Escherichia coli disease (IED) can lead to severe outcomes, particularly among older adults. However, the clinical burden of IED in the U.S. has not been well characterized.

methodsIED encounters among patients ≥ 60 years old were identified using the PINC AI™ Healthcare Database (10/01/2015-03/31/2020) by either a positive E. coli culture in blood or another normally sterile body site and ≥ 1 sign of systemic inflammatory response syndrome or signs of sepsis, or a positive E. coli culture in urine with urinary tract infection and signs of sepsis. Medical resource utilization, clinical outcomes, and E. coli isolate characteristics were descriptively reported during the first IED encounter and during the following year (observation period).

resultsOverall, 19,773 patients with IED were included (mean age: 76.8 years; 67.4% female; 78.5% with signs of sepsis). Most encounters involved community-onset IED (94.3%) and required hospitalization (96.5%; mean duration: 6.9 days), with 32.4% of patients being admitted to the intensive care unit (mean duration: 3.7 days). Most E. coli isolates were resistant to ≥ 1 antibiotic category (61.7%) and 34.4% were resistant to ≥ 3 antibiotic categories. Following their first IED encounter, 34.8% of patients were transferred to a skilled nursing/intermediate care facility, whereas 6.8% had died. During the observation period, 36.8% of patients were rehospitalized, 2.4% had IED recurrence, and in-hospital death increased to 10.9%.

conclusionsIED is associated with substantial clinical burden at first encounter with considerable long-term consequences. Findings demonstrate the need for increased IED awareness and highlight potential benefits of prevention.

Indexed as

Escherichia coliSepsisAgedAnti-Bacterial AgentsFemaleHospital MortalityHospitalsHumansMaleMiddle AgedUnited StatesAnti-Bacterial AgentsAntibiotic resistanceCase fatality rateInvasive Escherichia coli diseaseMedical resource utilizationTreatment patterns

Identifiers

PMID37608247
PMCPMC10464165
OpenAlexW4386048981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.